Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients

Twenty-four patients with metastatic cancer received two cycles of four daily immunizations with monocyte-derived dendritic cells (DC). DC were incubated with preheated autologous tumor lysate and subsequently with IFN-α, TNF-α, and polyinosinic:polycytidylic acid to attain type 1 maturation. One DC dose was delivered intranodally, under ultrasound control, and the rest intradermally in the opposite thigh. Cyclophosphamide (day −7), GM-CSF (days 1–4), and pegIFN alpha-2a (days 1 and 8) completed each treatment cycle. Pretreatment with cyclophosphamide decreased regulatory T cells to levels observed in healthy subjects both in terms of percentage and in absolute counts in peripheral blood. Treatment induced sustained elevations of IL-12 in serum that correlated with the output of IL-12p70 from cultured DC from each individual. NK activity in peripheral blood was increased and also correlated with the serum concentration of IL-12p70 in each patient. Circulating endothelial cells decreased in 17 of 18 patients, and circulating tumor cells markedly dropped in 6 of 19 cases. IFN-γ–ELISPOT responses to DC plus tumor lysate were observed in 4 of 11 evaluated cases. Tracing DC migration with [111In] scintigraphy showed that intranodal injections reached deeper lymphatic chains in 61% of patients, whereas with intradermal injections a small fraction of injected DC was almost constantly shown to reach draining inguinal lymph nodes. Five patients experienced disease stabilization, but no objective responses were documented. This combinatorial immunotherapy strategy is safe and feasible, and its immunobiological effects suggest potential activity in patients with minimal residual disease. A randomized trial exploring this hypothesis is currently ongoing.

[1]  K. Kakimi,et al.  [Dendritic cells for cancer immunotherapy]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[2]  J. Kirkwood,et al.  Helper Activity of Natural Killer Cells During the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells , 2011, Journal of immunotherapy.

[3]  S. Aamdal,et al.  hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes , 2011, Cancer Immunology, Immunotherapy.

[4]  H. Ueno,et al.  Recent Developments in Cancer Vaccines , 2011, The Journal of Immunology.

[5]  J. Banchereau,et al.  Type‐1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8+ T cells against prostate cancer cells and defined prostate cancer‐specific epitopes , 2011, The Prostate.

[6]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[8]  C. Punt,et al.  Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents , 2010, Clinical Cancer Research.

[9]  T. Taniguchi,et al.  Identification of a polyI:C-inducible membrane protein that participates in dendritic cell–mediated natural killer cell activation , 2010, The Journal of experimental medicine.

[10]  R. Steinman.  Some active areas of DC research and their medical potential , 2010, European journal of immunology.

[11]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Anna M. Keller,et al.  Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells , 2010, The Journal of experimental medicine.

[13]  H. Okada,et al.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. , 2010, Seminars in immunology.

[14]  F. Bertolini,et al.  Circulating endothelial cells as biomarkers in clinical oncology. , 2010, Microvascular research.

[15]  Zhuoshun Yang,et al.  Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. , 2010, Cancer research.

[16]  W. Heath,et al.  The CD8+ dendritic cell subset , 2010, Immunological reviews.

[17]  John M.L. Ebos,et al.  Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of respon , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Ley,et al.  Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. , 2009, Cancer research.

[19]  B. Sangro,et al.  Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? , 2009, Immunotherapy.

[20]  A. Schned,et al.  Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-α2a Therapy in Metastatic Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[21]  W. Oyen,et al.  Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients , 2009, Clinical Cancer Research.

[22]  I. Melero,et al.  Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes , 2009, British Journal of Cancer.

[23]  D. Kerr,et al.  A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma , 2009, Hepatology.

[24]  I. Tirapu,et al.  Freeze‐and‐thaw‐disrupted tumour cells impair the responsiveness of DC to TLR stimulation , 2008, European journal of immunology.

[25]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[26]  A. Melcher,et al.  Optimization of Dendritic Cell Loading With Tumor Cell Lysates for Cancer Immunotherapy , 2008, Journal of immunotherapy.

[27]  C. Figdor,et al.  Dendritic cell vaccination and immune monitoring , 2008, Cancer Immunology, Immunotherapy.

[28]  D. Pennington,et al.  Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. , 2008, The Journal of clinical investigation.

[29]  B. Neyns,et al.  Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  F. Belardelli,et al.  Dendritic cells and cytokines in immune rejection of cancer. , 2008, Cytokine & growth factor reviews.

[31]  L. Bracci,et al.  IFN‐α and Novel Strategies of Combination Therapy for Cancer , 2007 .

[32]  John E. Connolly,et al.  IL‐15‐induced human DC efficiently prime melanoma‐specific naive CD8+ T cells to differentiate into CTL , 2007, European journal of immunology.

[33]  I. Melero,et al.  Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer , 2007, Expert opinion on biological therapy.

[34]  E. Gilboa.  DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[35]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[36]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[37]  H. Ueno,et al.  Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells , 2006, Cancer Immunology, Immunotherapy.

[38]  G. Dranoff.  The Therapeutic Implications of Intratumoral Regulatory T Cells , 2005, Clinical Cancer Research.

[39]  L. Zitvogel,et al.  Natural killer cell–dendritic cell crosstalk in the initiation of immune responses , 2005, Expert opinion on biological therapy.

[40]  J. Prieto,et al.  Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8 , 2005, International journal of cancer.

[41]  J. Prieto,et al.  Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Zitvogel,et al.  NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. , 2004, Blood.

[43]  M. Atkins,et al.  Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses , 2004, Clinical Cancer Research.

[44]  T. Olencki,et al.  Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Kalluri,et al.  Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression , 2004, Cancer Research.

[46]  R. Foà,et al.  IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. , 2004, Blood.

[47]  P. Morel,et al.  Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function 1 , 2003, The Journal of Immunology.

[48]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[49]  Donna Niedzwiecki,et al.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. , 2003, Cancer research.

[50]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[51]  J. Prieto,et al.  αvβ3 Integrin-Mediated Adenoviral Transfer of Interleukin-12 at the Periphery of Hepatic Colon Cancer Metastases Induces VCAM-1 Expression and T-Cell Recruitment , 2001 .

[52]  J. Prieto,et al.  Alpha(v)beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  Lieping Chen,et al.  IL-12 gene therapy for cancer: in synergy with other immunotherapies. , 2001, Trends in immunology.

[54]  Eli Gilboa,et al.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. , 2000, Nature Medicine.

[55]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[56]  J. Prieto,et al.  Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. , 1999, Journal of immunology.

[57]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[58]  H. Rammensee,et al.  Priming of cytotoxic T lymphocytes by five heat‐aggregated antigens in vivo: Conditions, efficiency, and relation to antibody responses , 1997, European journal of immunology.

[59]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[60]  C. Punt,et al.  Cancer Therapy : Clinical Frequency of Circulating Tregs with Demethylated FOXP 3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents , 2011 .

[61]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[62]  L. Bracci,et al.  IFN-alpha and novel strategies of combination therapy for cancer. , 2007, Annals of the New York Academy of Sciences.

[63]  M. Serio,et al.  Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.

[64]  J. Teruya-Feldstein,et al.  Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. , 1999, Blood.

[65]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.